Christine E. Horak

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipilimu...

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who h...

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Nivolumab plus Ipilimumab in Advanced Melanoma

Concurrent therapy with nivolumab and ipilimumab had a manageable safety profile and provided clinical activity that appears to be distinct from that in published data on monoth...

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with niv...